Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free RNXT Stock Alerts

RenovoRx (RNXT) Financials

RenovoRx logo
$0.90 +0.02 (+1.82%)
As of 10:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for RenovoRx

Annual Income Statements for RenovoRx

This table shows RenovoRx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -3.80 -6.32 -9.89 -10 -8.81 -11
Consolidated Net Income / (Loss)		 -3.80 -6.32 -9.89 -10 -8.81 -11
Net Income / (Loss) Continuing Operations		 -3.80 -6.32 -9.89 -10 -8.81 -11
Total Pre-Tax Income 		-3.80 -6.32 -9.89 -10 -8.81 -11
Total Operating Income		 -3.20 -5.67 -9.95 -11 -11 -13
Total Gross Profit		 0.00 0.00 0.00 0.00 0.04 0.80
Total Revenue		 0.00 0.00 0.00 0.00 0.04 1.12
Operating Revenue		 - - - - 0.04 1.12
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.33
Operating Cost of Revenue		 - - - 0.00 0.00 0.33
Total Operating Expenses		 3.20 5.67 9.95 11 11 13
Selling, General & Admin Expense		 0.82 2.63 5.65 5.73 4.99 7.04
Research & Development Expense		 2.39 3.04 4.30 5.67 6.03 6.27
Total Other Income / (Expense), net		 -0.59 -0.65 0.06 1.16 2.16 1.34
Interest & Investment Income		 - -0.83 0.06 0.11 0.38 0.43
Other Income / (Expense), net		 -0.01 0.12 0.00 1.06 1.77 0.92
Basic Earnings per Share		 ($1.72) ($1.21) ($1.09) - ($0.40) ($0.32)
Weighted Average Basic Shares Outstanding		 2.21M 5.22M 9.05M 16.87M 22.27M 35.33M
Diluted Earnings per Share		 ($1.72) - ($1.09) - ($0.40) ($0.32)
Weighted Average Diluted Shares Outstanding		 2.21M 5.22M 9.05M 16.87M 22.27M 35.33M
Weighted Average Basic & Diluted Shares Outstanding		 2.21M 5.22M 9.10M 16.87M 36.55M 45.05M

Quarterly Income Statements for RenovoRx

This table shows RenovoRx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.42 -3.23 -1.08 -2.39 -2.47 -2.88 -2.42 -2.90 -2.91 -2.94 -3.52
Consolidated Net Income / (Loss)		 -1.42 -3.23 -1.08 -2.39 -2.47 -2.88 -2.42 -2.90 -2.91 -2.94 -3.52
Net Income / (Loss) Continuing Operations		 -1.42 -3.23 -1.08 -2.39 -2.47 -2.88 -2.42 -2.90 -2.91 -2.94 -3.52
Total Pre-Tax Income 		-1.42 -3.23 -1.08 -2.39 -2.47 -2.88 -2.42 -2.90 -2.91 -2.94 -3.52
Total Operating Income		 -2.98 -1.78 -2.48 -3.03 -2.83 -2.63 -3.11 -2.68 -3.20 -3.52 -3.47
Total Gross Profit		 0.00 - 0.00 0.00 0.00 0.04 0.10 0.27 0.21 0.21 0.48
Total Revenue		 0.00 - 0.00 0.00 0.00 0.04 0.20 0.42 0.27 0.24 0.56
Operating Revenue		 - - 0.00 0.00 0.00 0.04 0.20 0.42 0.27 0.24 0.56
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.09 0.15 0.05 0.03 0.08
Operating Cost of Revenue		 - - 0.00 0.00 0.00 - 0.09 0.15 0.05 0.03 0.08
Total Operating Expenses		 2.98 1.78 2.48 3.03 2.83 2.68 3.21 2.95 3.41 3.73 3.95
Selling, General & Admin Expense		 1.35 1.00 1.22 1.49 1.18 1.10 1.57 1.52 1.73 2.22 2.72
Research & Development Expense		 1.63 0.78 1.26 1.54 1.65 1.58 1.64 1.43 1.69 1.52 1.23
Total Other Income / (Expense), net		 1.56 -1.45 1.40 0.65 0.36 -0.25 0.69 -0.22 0.29 0.58 -0.05
Interest & Investment Income		 0.04 0.01 0.04 0.14 0.12 0.09 0.11 0.13 0.11 0.08 0.05
Other Income / (Expense), net		 1.52 - 1.36 0.51 0.23 -0.33 0.58 -0.35 0.18 0.51 -0.10
Basic Earnings per Share		 ($0.13) - ($0.07) ($0.10) ($0.10) ($0.13) ($0.08) ($0.08) ($0.08) ($0.08) ($0.09)
Weighted Average Basic Shares Outstanding		 10.69M 16.87M 14.95M 24.05M 24.94M 22.27M 31.40M 36.58M 36.65M 35.33M 38.03M
Diluted Earnings per Share		 ($0.13) - ($0.07) ($0.10) ($0.10) ($0.13) ($0.08) ($0.08) ($0.08) ($0.08) ($0.09)
Weighted Average Diluted Shares Outstanding		 10.69M 16.87M 14.95M 24.05M 24.94M 22.27M 31.40M 36.58M 36.65M 35.33M 38.03M
Weighted Average Basic & Diluted Shares Outstanding		 10.69M 16.87M 23.95M 23.99M 24.00M 36.55M 36.57M 36.65M 36.65M 45.05M 45.10M

Annual Cash Flow Statements for RenovoRx

This table details how cash moves in and out of RenovoRx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.33 13 -11 -3.22 5.98 -0.13
Net Cash From Operating Activities		 -3.53 -5.92 -8.81 -10 -9.13 -11
Net Cash From Continuing Operating Activities		 -3.53 -5.92 -8.81 -10 -9.13 -11
Net Income / (Loss) Continuing Operations		 -3.80 -6.32 -9.89 -10 -8.81 -11
Consolidated Net Income / (Loss)		 -3.80 -6.32 -9.89 -10 -8.81 -11
Depreciation Expense		 - - - - 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.15 -0.03 0.64 -0.63 -0.59 0.44
Changes in Operating Assets and Liabilities, net		 -0.37 -0.27 0.43 0.61 0.28 -0.25
Net Cash From Investing Activities		 0.00 -0.02 -2.03 2.03 -0.01 -0.00
Net Cash From Continuing Investing Activities		 0.00 -0.02 -2.03 2.03 -0.01 -0.00
Purchase of Property, Plant & Equipment		 - - - 0.00 -0.01 -0.00
Net Cash From Financing Activities		 3.20 19 0.04 5.01 15 11
Net Cash From Continuing Financing Activities		 3.20 19 0.04 5.01 15 11
Repurchase of Common Equity		 - - - - -2.23 -1.30
Issuance of Common Equity		 0.00 15 0.00 5.00 17 12
Other Financing Activities, net		 0.04 2.79 0.04 0.01 0.10 0.04
Cash Interest Paid		 - - - 0.01 0.02 0.02
Cash Income Taxes Paid		 - - - 0.04 0.00 0.00

Quarterly Cash Flow Statements for RenovoRx

This table details how cash moves in and out of RenovoRx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -2.73 -2.05 3.22 7.35 -2.18 -2.41 7.43 -2.27 -2.27 -3.02 5.34
Net Cash From Operating Activities		 -2.73 -2.05 -2.20 -2.30 -2.19 -2.43 -3.38 -2.30 -2.27 -3.02 -3.71
Net Cash From Continuing Operating Activities		 -2.73 -2.05 -2.20 -2.30 -2.19 -2.43 -3.38 -2.30 -2.27 -3.02 -3.71
Net Income / (Loss) Continuing Operations		 -1.42 -3.23 -1.08 -2.39 -2.47 -2.88 -2.42 -2.90 -2.91 -2.94 -3.52
Consolidated Net Income / (Loss)		 -1.42 -3.23 -1.08 -2.39 -2.47 -2.88 -2.42 -2.90 -2.91 -2.94 -3.52
Depreciation Expense		 - - 0.00 - - - 0.00 0.00 -0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 -1.28 1.60 -0.94 -0.26 0.02 0.59 -0.27 0.72 0.20 -0.20 0.44
Changes in Operating Assets and Liabilities, net		 -0.03 -0.43 -0.19 0.36 0.26 -0.14 -0.69 -0.12 0.45 0.12 -0.63
Net Cash From Investing Activities		 - - 0.00 - - -0.01 -0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - -0.01 -0.00 - - - 0.00
Purchase of Property, Plant & Equipment		 - - 0.00 - - -0.01 -0.00 - - - 0.00
Net Cash From Financing Activities		 - - 5.42 9.65 0.02 0.03 11 0.03 - - 9.05
Net Cash From Continuing Financing Activities		 - - 5.42 9.65 0.02 0.03 11 0.03 - - 9.05
Repurchase of Common Equity		 - - - - - -2.23 -1.30 - - - -0.95
Issuance of Common Equity		 - - 5.38 - - - 12 - - - 10
Other Financing Activities, net		 - - 0.04 15 0.02 -15 0.01 0.03 1.30 -12 0.00
Cash Interest Paid		 - - 0.00 - - 0.02 0.01 0.00 -0.01 0.02 0.00
Cash Income Taxes Paid		 - - 0.00 - - 0.00 0.00 0.00 - -0.00 0.00

Annual Balance Sheets for RenovoRx

This table presents RenovoRx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.91 16 7.27 1.47 8.12 8.10
Total Current Assets		 1.91 16 7.27 1.47 7.83 7.89
Cash & Equivalents		 1.80 15 4.39 1.17 7.15 7.02
Accounts Receivable		 - - - 0.00 0.04 0.14
Inventories, net		 - - - - 0.00 0.19
Prepaid Expenses		 0.12 1.09 0.83 0.17 0.33 0.32
Other Current Assets		 - - - 0.13 0.30 0.22
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.01 0.01
Total Noncurrent Assets		 0.00 0.01 0.00 0.00 0.28 0.19
Other Noncurrent Operating Assets		 0.00 - 0.00 0.00 0.28 0.19
Total Liabilities & Shareholders' Equity		 1.91 16 7.27 1.47 8.12 8.10
Total Liabilities		 4.12 0.94 1.10 4.47 3.64 2.67
Total Current Liabilities		 4.10 0.94 1.10 1.18 1.91 1.96
Accounts Payable		 0.16 0.53 0.53 0.56 0.59 0.80
Accrued Expenses		 0.31 0.41 0.57 0.61 1.32 1.16
Total Noncurrent Liabilities		 0.02 0.00 0.00 3.29 1.73 0.71
Other Noncurrent Operating Liabilities		 0.02 - 0.00 3.29 1.73 0.71
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -15 15 6.16 -3.00 4.48 5.42
Total Preferred & Common Equity		 -15 15 6.16 -3.00 4.48 5.42
Total Common Equity		 -15 15 6.16 -3.00 4.48 5.42
Common Stock		 0.30 37 37 38 55 67
Retained Earnings		 -15 -21 -31 -41 -50 -61

Quarterly Balance Sheets for RenovoRx

This table presents RenovoRx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 3.52 4.79 12 10 16 14 11 14
Total Current Assets		 3.48 4.66 12 10 16 13 11 14
Cash & Equivalents		 3.23 4.39 12 9.56 15 12 10 12
Accounts Receivable		 - - - - 0.24 0.36 0.17 0.28
Inventories, net		 - - - - - - 0.27 0.38
Prepaid Expenses		 0.25 0.27 0.26 0.47 0.48 0.43 0.35 0.50
Other Current Assets		 - - - - 0.44 0.29 0.15 0.20
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.08
Total Noncurrent Assets		 0.04 0.13 0.00 0.00 0.26 0.24 0.21 0.17
Other Noncurrent Operating Assets		 0.04 0.13 0.00 0.00 0.26 0.24 0.21 0.17
Total Liabilities & Shareholders' Equity		 3.52 4.79 12 10 16 14 11 14
Total Liabilities		 3.51 3.02 2.73 2.96 2.86 3.00 3.13 2.70
Total Current Liabilities		 1.61 1.09 1.31 1.77 1.74 1.56 1.88 1.92
Accounts Payable		 0.35 0.36 0.44 0.69 0.97 0.67 0.87 1.12
Accrued Expenses		 1.26 0.74 0.87 1.09 0.77 0.89 1.02 0.80
Total Noncurrent Liabilities		 1.91 1.93 1.42 1.19 1.12 1.45 1.24 0.78
Other Noncurrent Operating Liabilities		 1.91 1.93 1.42 1.19 1.12 1.45 1.24 0.78
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.01 1.77 9.27 7.07 13 11 8.08 11
Total Preferred & Common Equity		 0.01 1.77 9.27 7.07 13 11 8.08 11
Total Common Equity		 0.01 1.77 9.27 7.07 13 11 8.08 11
Common Stock		 38 44 54 54 66 66 67 76
Retained Earnings		 -38 -42 -45 -47 -53 -56 -58 -65

Annual Metrics And Ratios for RenovoRx

This table displays calculated financial ratios and metrics derived from RenovoRx's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 8,908,150.00 9,097,701.00 10,693,580.00 24,001,339.00 36,649,916.00
DEI Adjusted Shares Outstanding		 0.00 8,908,150.00 9,097,701.00 10,693,580.00 24,001,339.00 36,649,916.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.71 -1.09 -0.96 -0.37 -0.30
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 2,511.63%
EBITDA Growth		 0.00% -78.03% -105.12% -4.02% 11.04% -26.04%
EBIT Growth		 0.00% -72.91% -79.14% -3.96% 11.04% -26.06%
NOPAT Growth		 0.00% -77.00% -75.45% -14.53% 3.74% -14.04%
Net Income Growth		 0.00% -66.51% -56.37% -3.47% 13.86% -26.71%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 20.00%
Operating Cash Flow Growth		 0.00% -67.69% -48.94% -16.42% 11.05% -20.25%
Free Cash Flow Firm Growth		 0.00% 0.00% -19.25% 37.51% -124.84% -7.14%
Invested Capital Growth		 0.00% 111.63% -276.43% -1,406.50% 35.87% 40.13%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 21.01%
EBITDA Q/Q Growth		 0.00% 0.00% 1.78% 12.29% 9.07% -0.44%
EBIT Q/Q Growth		 0.00% 0.00% 1.82% 12.29% 9.07% -0.46%
NOPAT Q/Q Growth		 0.00% 0.00% 1.84% 3.33% -8.45% -7.66%
Net Income Q/Q Growth		 0.00% 0.00% 1.97% -11.69% 3.81% -0.57%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% -36.69% 9.05% -3.76% -4.31% -5.68%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 18.35% -17.51% -13.52%
Invested Capital Q/Q Growth		 0.00% 0.00% -914.71% -29.60% -7.38% 18.51%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 70.88%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -21,390.70% -1,032.32%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -25,511.63% -1,113.98%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -21,390.70% -1,032.50%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -20,497.67% -994.48%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 118.28% 113.90% 99.43% 98.96% 95.83% 96.32%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 172.24% -96.23% -91.94% -646.98% -1,192.69% -225.62%
Cash Return on Invested Capital (CROIC)		 0.00% -3,488.34% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -191.94% -143.03%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -183.93% -137.77%
Return on Common Equity (ROCE)		 1,144.86% -5.07% -91.94% -646.98% -1,192.69% -225.62%
Return on Equity Simple (ROE_SIMPLE)		 25.91% -41.20% -160.46% 341.07% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.24 -3.97 -6.97 -7.98 -7.68 -8.76
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -17,858.14% -779.79%
Net Nonoperating Expense Percent (NNEP)		 181.89% -32.84% -27.03% -59.24% -27.26% -34.01%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 265.91% -171.48% -161.51%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 29.12%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 11,600.00% 626.63%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 14,011.63% 558.24%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 25,611.63% 1,184.86%
Earnings before Interest and Taxes (EBIT)		 -3.21 -5.55 -9.95 -10 -9.20 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.72 -4.85 -9.94 -10 -9.20 -12
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.81 3.47 0.00 6.91 5.68
Price to Tangible Book Value (P/TBV)		 0.00 2.81 3.47 0.00 6.91 5.68
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 720.04 27.42
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 177.86 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 553.67 21.16
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 -1.20 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.39 -1.09 -1.01 -2.41 -5.63 -1.43
Leverage Ratio		 -0.87 1.38 1.09 2.76 6.48 1.64
Compound Leverage Factor		 -1.03 1.58 1.09 2.73 6.21 1.58
Debt to Total Capital		 595.51% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 595.51% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 2,797.98% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -3,293.48% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.97 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -0.31 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.18 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -0.38 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -15.42 25.76 2.13 -59.29 -6.42 -7.41
Noncontrolling Interest Sharing Ratio		 -564.67% 94.73% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.47 17.36 6.59 1.25 4.10 4.02
Quick Ratio		 0.44 16.20 5.84 1.00 3.77 3.65
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.48 -6.53 -4.08 -9.18 -9.83
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -76,041.67% -548,650.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -6.01 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -6.01 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.01 0.14
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 12.34
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 93.58
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.47
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 29.58
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 772.97
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -743.40
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -1.35 0.16 -0.28 -4.17 -2.68 -1.60
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.01 -0.53
Increase / (Decrease) in Invested Capital		 0.00 1.51 -0.43 -3.90 1.50 1.07
Enterprise Value (EV)		 30 28 15 23 24 24
Market Capitalization		 17 43 21 24 31 31
Book Value per Share		 ($6.62) $1.72 $0.68 ($0.28) $0.19 $0.15
Tangible Book Value per Share		 ($6.62) $1.72 $0.68 ($0.28) $0.19 $0.15
Total Capital		 0.45 15 6.16 -3.00 4.48 5.42
Total Debt		 2.65 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.86 -15 -6.44 -1.17 -7.15 -7.02
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.33 0.15 -0.28 -0.88 -1.24 -1.09
Debt-free Net Working Capital (DFNWC)		 0.46 15 6.16 0.29 5.92 5.93
Net Working Capital (NWC)		 -2.19 15 6.16 0.29 5.92 5.93
Net Nonoperating Expense (NNE)		 1.56 2.35 2.92 2.25 1.14 2.41
Net Nonoperating Obligations (NNO)		 0.86 -15 -6.44 -1.17 -7.15 -7.02
Total Depreciation and Amortization (D&A)		 0.49 0.71 0.01 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -2,872.09% -97.33%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 13,765.12% 528.14%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 13,765.12% 528.14%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.21) ($1.09) ($0.99) $0.00 ($0.32)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 9.03M 9.05M 10.29M 36.55M 35.33M
Adjusted Diluted Earnings per Share		 $0.00 ($1.21) $0.00 ($0.99) $0.00 ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 9.03M 9.10M 10.29M 36.55M 35.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.21) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 5.22M 9.10M 16.87M 36.55M 45.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.24 -3.97 -6.97 -7.98 -7.68 -8.76
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -17,858.14% -779.79%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -20,497.67% -994.48%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -5.47 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -3.82 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -5.47 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -3.82 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -25.32% -11.63%

Quarterly Metrics And Ratios for RenovoRx

This table displays calculated financial ratios and metrics derived from RenovoRx's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 10,693,080.00 10,693,580.00 16,865,975.00 23,951,825.00 23,986,709.00 24,001,339.00 36,546,752.00 36,572,232.00 36,645,884.00 36,649,916.00 45,052,706.00
DEI Adjusted Shares Outstanding		 10,693,080.00 10,693,580.00 16,865,975.00 23,951,825.00 23,986,709.00 24,001,339.00 36,546,752.00 36,572,232.00 36,645,884.00 36,649,916.00 45,052,706.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.13 -0.30 -0.06 -0.10 -0.10 -0.12 -0.07 -0.08 -0.08 -0.08 -0.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 453.49% 185.79%
EBITDA Growth		 32.16% 18.19% 65.87% -6.31% -77.25% -66.74% -126.86% -19.79% -16.61% -1.76% -41.19%
EBIT Growth		 32.16% 18.19% 65.87% -6.31% -77.25% -66.74% -126.95% -19.83% -16.57% -1.79% -41.17%
NOPAT Growth		 -38.04% 18.11% 24.07% 10.10% 5.20% -48.11% -25.61% 11.73% -13.15% -33.81% -11.54%
Net Income Growth		 33.47% -49.68% 66.96% -2.66% -73.89% 10.82% -124.91% -21.18% -17.85% -2.19% -45.50%
EPS Growth		 45.83% 0.00% 80.56% 54.55% 23.08% 0.00% -14.29% 20.00% 20.00% 38.46% -12.50%
Operating Cash Flow Growth		 -2.10% -22.13% 18.55% 17.11% 19.57% -18.36% -53.40% -0.22% -3.46% -24.28% -9.70%
Free Cash Flow Firm Growth		 167.84% 344.43% 117.60% -351.34% -332.23% -225.92% -899.91% 39.55% -2.16% -5.99% 18.31%
Invested Capital Growth		 -9,570.59% -1,406.50% -461.46% 48.17% 22.61% 35.87% 45.65% 32.27% 21.11% 40.13% 23.02%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 358.14% 114.21% -36.97% -10.53% 136.55%
EBITDA Q/Q Growth		 38.41% -21.38% 37.37% -127.04% -2.69% -14.18% 14.78% -19.88% 0.03% 0.36% -18.24%
EBIT Q/Q Growth		 38.41% -21.38% 37.37% -127.04% -2.69% -14.18% 14.75% -19.87% 0.10% 0.30% -18.24%
NOPAT Q/Q Growth		 11.61% 40.43% -39.34% -22.54% 6.79% 6.93% -18.16% 13.89% -19.49% -10.06% 1.50%
Net Income Q/Q Growth		 38.93% -127.09% 66.66% -122.03% -3.43% -16.47% 15.91% -19.63% -0.59% -1.00% -19.72%
EPS Q/Q Growth		 40.91% 0.00% 0.00% -42.86% 0.00% -30.00% 38.46% 0.00% 0.00% 0.00% -12.50%
Operating Cash Flow Q/Q Growth		 1.55% 24.74% -7.36% -4.22% 4.48% -10.76% -39.14% 31.91% 1.39% -33.04% -22.81%
Free Cash Flow Firm Q/Q Growth		 -33.70% 127.47% -84.10% -1,147.84% 38.74% -23.33% -1.04% 20.82% -3.53% -27.96% 22.13%
Invested Capital Q/Q Growth		 32.44% -29.60% 37.17% 5.80% -0.89% -7.38% 46.75% -17.40% -17.51% 18.51% 31.52%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 52.28% 63.98% 80.08% 88.24% 85.08%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -6,890.70% -1,281.73% -717.30% -1,137.59% -1,266.81% -633.21%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -6,120.93% -1,578.68% -634.60% -1,203.01% -1,479.83% -616.16%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -6,890.70% -1,282.23% -717.54% -1,137.22% -1,267.23% -633.39%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -6,693.02% -1,228.43% -686.02% -1,094.74% -1,235.71% -625.40%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.06% 181.60% 96.68% 94.54% 95.22% 97.13% 95.80% 95.61% 96.26% 97.51% 98.74%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -224.70% -646.98% -320.57% -155.12% -258.95% -1,192.69% -136.13% -107.11% -146.61% -225.62% -100.48%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -61.83% -29.59% -37.04% -99.39% -175.55% -62.92%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -60.06% -28.35% -35.42% -95.67% -171.18% -62.13%
Return on Common Equity (ROCE)		 -224.70% -646.98% -320.57% -155.12% -258.95% -1,192.69% -136.13% -107.11% -146.61% -225.62% -100.48%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -455.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.09 -1.24 -1.73 -2.12 -1.98 -1.84 -2.18 -1.87 -2.24 -2.47 -2.43
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -4,284.65% -1,105.08% -444.22% -842.11% -1,035.88% -431.31%
Net Nonoperating Expense Percent (NNEP)		 11.77% -52.10% 16.20% -3.00% -7.68% -24.87% -2.56% -8.48% -6.85% -6.71% -8.11%
Return On Investment Capital (ROIC_SIMPLE)		 - 41.46% -98.09% -22.91% -28.00% -41.14% -16.55% -17.62% -27.73% -45.47% -21.56%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 47.72% 36.02% 19.92% 11.76% 14.92%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 2,555.81% 797.46% 360.66% 649.62% 931.09% 483.13%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 3,665.12% 833.50% 337.91% 633.46% 636.97% 218.12%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 6,220.93% 1,630.96% 698.58% 1,283.08% 1,568.07% 701.24%
Earnings before Interest and Taxes (EBIT)		 -1.46 -1.78 -1.11 -2.53 -2.60 -2.96 -2.53 -3.03 -3.03 -3.02 -3.57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.46 -1.78 -1.11 -2.53 -2.60 -2.96 -2.53 -3.03 -3.03 -3.02 -3.57
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2,370.30 0.00 8.11 2.92 3.60 6.91 1.81 4.52 5.76 5.68 4.04
Price to Tangible Book Value (P/TBV)		 2,370.30 0.00 8.11 2.92 3.60 6.91 1.81 4.52 5.76 5.68 4.04
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 720.04 99.01 72.65 50.15 27.42 30.56
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 553.67 38.25 54.05 39.33 21.16 22.26
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.39 -2.41 -1.62 -1.69 -1.81 -5.63 -1.27 -1.21 -1.29 -1.43 -1.10
Leverage Ratio		 1.57 2.76 1.86 1.75 1.91 6.48 1.39 1.29 1.40 1.64 1.23
Compound Leverage Factor		 1.52 5.01 1.80 1.66 1.82 6.30 1.34 1.23 1.35 1.60 1.21
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -13.49 -40.01 -9.45 1.09 -1.32 -3.88 0.93 4.27 1.79 -3.92 3.89
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.17 1.25 4.26 9.16 5.66 4.10 9.07 8.61 5.83 4.02 7.15
Quick Ratio		 2.01 1.00 4.02 8.96 5.40 3.77 8.54 8.15 5.42 3.65 6.58
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1.17 2.65 0.42 -4.42 -2.71 -3.34 -3.37 -2.67 -2.77 -3.54 -2.76
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% -20,250.00% -169,050.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.05 0.09 0.14 0.10
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.34 5.71
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 93.58 33.09
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.14 0.44 0.38 0.47 0.30
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 29.58 63.98
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 2,568.59 822.73 949.12 772.97 1,200.93
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 -2,568.59 -822.73 -949.12 -743.40 -1,136.95
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.22 -4.17 -2.62 -2.47 -2.49 -2.68 -1.43 -1.67 -1.97 -1.60 -1.10
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -0.01 -0.12 -0.32 -0.42 -0.53 -1.18
Increase / (Decrease) in Invested Capital		 -3.25 -3.90 -2.16 2.30 0.73 1.50 1.20 0.80 0.53 1.07 0.33
Enterprise Value (EV)		 11 23 9.94 15 16 24 9.18 36 36 24 33
Market Capitalization		 14 24 14 27 25 31 24 48 47 31 46
Book Value per Share		 $0.00 ($0.28) $0.17 $0.39 $0.29 $0.19 $0.55 $0.29 $0.22 $0.15 $0.25
Tangible Book Value per Share		 $0.00 ($0.28) $0.17 $0.39 $0.29 $0.19 $0.55 $0.29 $0.22 $0.15 $0.25
Total Capital		 0.01 -3.00 1.77 9.27 7.07 4.48 13 11 8.08 5.42 11
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -3.23 -1.17 -4.39 -12 -9.56 -7.15 -15 -12 -10 -7.02 -12
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.35 -0.88 -0.82 -1.05 -1.30 -1.24 -0.57 -0.48 -0.95 -1.09 -0.56
Debt-free Net Working Capital (DFNWC)		 1.87 0.29 3.57 11 8.26 5.92 14 12 9.10 5.93 12
Net Working Capital (NWC)		 1.87 0.29 3.57 11 8.26 5.92 14 12 9.10 5.93 12
Net Nonoperating Expense (NNE)		 -0.67 1.98 -0.66 0.27 0.49 1.04 0.24 1.02 0.67 0.48 1.09
Net Nonoperating Obligations (NNO)		 -3.23 -1.17 -4.39 -12 -9.56 -7.15 -15 -12 -10 -7.02 -12
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -2,872.09% -238.75% -71.75% -102.16% -97.33% -37.74%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 13,765.12% 5,837.08% 1,788.37% 980.17% 528.14% 792.48%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 13,765.12% 5,837.08% 1,788.37% 980.17% 528.14% 792.48%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.13) $0.00 ($0.07) ($0.10) ($0.10) ($0.13) ($0.08) ($0.08) ($0.08) ($0.08) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 10.69M 16.87M 14.95M 24.05M 24.94M 22.27M 31.40M 36.58M 36.65M 35.33M 38.03M
Adjusted Diluted Earnings per Share		 ($0.13) $0.00 ($0.07) ($0.10) ($0.10) ($0.13) ($0.08) ($0.08) ($0.08) ($0.08) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 10.69M 16.87M 14.95M 24.05M 24.94M 22.27M 31.40M 36.58M 36.65M 35.33M 38.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 10.69M 16.87M 23.95M 23.99M 24.00M 36.55M 36.57M 36.65M 36.65M 45.05M 45.10M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.09 -1.24 -1.73 -2.12 -1.98 -1.84 -2.18 -1.87 -2.24 -2.47 -2.43
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -4,284.65% -1,105.08% -444.22% -842.11% -1,035.88% -431.31%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -6,693.02% -1,228.43% -686.02% -1,094.74% -1,235.71% -625.40%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -25.32% 0.00% 0.00% 0.00% -11.63% -7.77%

Financials Breakdown Chart

RenovoRx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, RenovoRx's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

RenovoRx's net income appears to be on an upward trend, with a most recent value of -$11.17 million in 2025, rising from -$3.80 million in 2020. The previous period was -$8.81 million in 2024. View RenovoRx's forecast to see where analysts expect RenovoRx to go next.

RenovoRx's total operating income in 2025 was -$12.51 million, based on the following breakdown:
  • Total Gross Profit: $796 thousand
  • Total Operating Expenses: $13.31 million

Over the last 5 years, RenovoRx's total revenue changed from $0.00 in 2020 to $1.12 million in 2025, a change of 112,300,000.0%.

RenovoRx's total liabilities were at $2.67 million at the end of 2025, a 26.6% decrease from 2024, and a 35.1% decrease since 2020.

In the past 5 years, RenovoRx's cash and equivalents has ranged from $1.17 million in 2023 to $15.19 million in 2021, and is currently $7.02 million as of their latest financial filing in 2025.

Over the last 5 years, RenovoRx's book value per share changed from -6.62 in 2020 to 0.15 in 2025, a change of -102.2%.


Related Companies

Financial statements for NASDAQ:RNXT last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel